Dr Ruchir Bhandari

18/01/2026

Sharing my interview featured in The Deccan Chronicle

In "Hair This Straight Talk!", I share medical perspectives on the potential health risks associated with chemical hair-straightening treatments and the importance of making informed, science backed choices.

Read the full interview here: https://Inkd.in/g6SatD4U
Ruchir Bhandari

15/10/2025

We would like to invite all to our second episode of our expert Webinar series -

Incancers®: Global Insights in Precision oncology
Advancements in & Therapy (Updates from ASCO/ASTRO 2025)

🎤 International Speaker:
Christian Hyde, MD
Proton Therapy Specialist, Wayne State University, USA

📌 15th October 2025 (Wed)
🕓 4:00 – 5:00 PM IST

🎤 Moderator:
Ruchir Bhandari
Consultant & Head of Cyberknife, MGH Jaipur

🔗 Register Now (free) and the zoom link will be shared on your email.
https://lnkd.in/euwXPJQe

📍 Organized by
Department of Radiation Oncology & CyberKnife, Mahatma Gandhi Hospital Jaipur

🎓Academic partner
Incancers®

This link will take you to a page that’s not on LinkedIn

16/09/2025

✨ A heartfelt thank you to everyone who joined us for the 1st episode of our webinar series Incancers® - Global Insights in Precision Oncology”

We were truly honored to host Dr Arjun Sahgal, a global leader in Gamma Knife Radiosurgery, ISRS President, and prolific researcher, who shared his expertise and insights with such clarity and passion.

We are excited to continue building this platform for collaborative learning in precision oncology from global experts.

🔜 Stay tuned for our 2nd episode on Proton Therapy, coming up next month!

29/10/2024

Glad to be a part of an engaging panel discussion on "Recent Advances in the management of advanced hepatocellular cancers" and the role of Cyberknife Radiosurgery for these patients at the Liver Summit, Sept 2024, Jaipur.

19/10/2024

Newer indications of radiotherapy are adding more years to life.

The world’s largest clinical trial using radiotherapy to treat advanced non-small cell lung cancer (NSCLC) has opened at The Christie.

The study aims to recruit nearly 1,000 patients newly diagnosed with lung cancer that has spread to other parts of the body.

The aim is to understand how effective advanced radiotherapy techniques are in treating advanced NSCLC.

Dr David Woolf, consultant oncologist at The Christie, explained: “Most people with stage IV NSCLC are eligible for this trial so it’s very inclusive. This is the first time we have delivered a trial in radiotherapy for this group of patients in 20 years so it’s a big deal.

"Techniques have advanced to such an extent in this time that we believe that radiotherapy can bring additional benefit to patients undergoing their standard treatments. This study aims to provide enough evidence to change clinical practice globally and could help up to a million people a year worldwide.”

More
👉 https://bit.ly/3Udc1nH